The global stereotactic radiation therapy market was valued at US$ 3.7 Billion in 2022 and is expected to reach US$ 7.9 Billion by 2033. The linear accelerator radiosurgery systems with around 68.9% value share, has topped the global market within the product category in 2022 and is expected to grow at a CAGR of close to 7.3% over the forecast period (2023 to 2033)
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 3.7 Billion |
| Market Value 2023 | US$ 3.9 Billion |
| Market Value 2033 | US$ 7.9 Billion |
| CAGR 2023 to 2033 | 7.3% |
| Market Share of Top 5 Countries | 62.6% |
| Key Market Players | Mevion Medical Systems, Inc., Accuray Incorporated, MASEP Medical Science & Technology Development (Shenzhen) Co, Akesis, Inc., Elekta, Hitachi, Ltd. (Mitsubishi Electric Corporation), Siemens Healthineers AG (Varian Medical Systems, Inc.), Ion Beam Applications, ProTom International, Pronova Solutions, Sumitomo Heavy Industries, Ltd., Provision Cares, Optivus Proton Therapy Inc., Advanced Oncotherapy, Sun Nuclear Corporation, and B dot Medical Inc. (partnered with Toshiba) |
The treatment of functional disorders and tiny brain tumors with stereotactic radiosurgery (SRS), a non-surgical radiation therapy has been growing rapidly. In comparison to conventional therapy, it can administer precisely focused radiation in fewer high-dose treatments, helping to maintain healthy tissue. Stereotactic body radiation (SBRT) is the name of the procedure utilised for the treatment of body tumors using SRS.
Small brain tumors and other abnormalities in function of the brain were the original target conditions for the development of stereotactic radiosurgery (SRS), a very precise radiation therapy technique. Stereotactic body radiotherapy (SBRT) is a technique used to treat body tumors that uses the same concepts as cranial SRS, namely precise radiation with delivery accuracy to within one to two millimetres.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market for stereotactic radiation therapy (SRT) was around 55.3% of the overall US$ 6.6 Billion of the global radiation therapy market in 2022.
The rapid advancement of technology in the radiation therapy segment in recent years has pushed the expansion of the SRT market. The rising prevalence of cancer disorders and the growing geriatric population is driving the growing need for rapid improvement in SRT technology around the world.
The growing research for development of cost-effective stereotactic radiotherapy, and increasing awareness regarding radiotherapy are few other growth drivers increasing the demand for stereotactic radiation therapy. Globally, radiation therapy is the treatment of choice for over 7 out of 10 patients with cancers of the breast, head and neck, lung or oesophagus
There is a huge demand for radiation therapy systems in low and middle income countries as cancer kills more population than HIV, TB and malaria combines. This affects the lives of patients and their families with huge physical, emotional and financial crisis.
Increase in cancer cases and the sophistication of new treatment protocols drives the market for newly developed automated SRT systems which makes treatment rapid and cost-effective.
Owed to the above factors, the global market is projected to grow at CAGR of 7.3% in forecasted period.
For several decades, lung cancer has been the most frequent cancer in the world.
In a study conducted at the Markey Cancer Centre in 2021, stereotactic body radiation therapy (SBRT) was utilized for persons with stage I or stage II lung cancer who are not adequate for surgical procedure. Because X-rays are well focused and healthy tissue receives relatively little radiation, SBRT side effects are rare. This non-surgical therapy option with less side effects of the SBRT is enticing patients and clinicians to use it.
Stereotactic radiation therapy provides good tumor control rates while delivering precise doses. In comparison to conventional radiation therapy, it allows for larger radiation doses to be provided in fewer treatment sessions. This leads to better outcomes, such as higher tumor control rates and higher survival rates for some malignancies. The possibility of shorter treatment sessions and fewer side effects leads to the growing use of stereotactic radiation therapy.
Stereotactic radiation therapy is a non-invasive or minimally invasive therapeutic option that, in some situations, avoids the need for surgery. It can be used to treat both primary and metastatic tumors, offering a non-invasive alternative to invasive methods. Stereotactic radiation therapy is appealing to patients and physicians due to its ability to deliver targeted radiation without requiring open surgery.
All the above factors are expected to contribute as the driving forces for the market growth over forecast period.
Principal Consultant
Moving targets, such as tumors impacted by respiration or other physiological motion, can be difficult to target and track accurately in stereotactic radiation therapy. Techniques such as respiratory gating or tumor tracking may be used to solve this issue, but they complicate the treatment process and necessitate more resources.
Stereotactic radiation therapy necessitates extensive technical knowledge and specialised training. SRT's success is dependent on accurate treatment planning, target localization, and precision radiation delivery. Because of the complexities of the therapy procedure, trained radiation oncologists, medical physicists, and dosimetrists are required, which can be a constraint in some circumstances.
While stereotactic radiation therapy has demonstrated excellent short-term outcomes, there is a need for more long-term data on its effectiveness and potential late toxicities. Long-term follow-up studies are essential to evaluate the durability of tumor control and the impact on patient survival and quality of life. The limited availability of long-term data may influence decision-making and adoption of SRT in certain scenarios.
The U.S. occupies 33.7% of market share in 2022 globally. The growing prevalence of cancer and the need for effective treatment choices drive the demand for sophisticated radiation therapy techniques like stereotactic radiation therapy. As the incidence of cancer rises, so does the demand for precise and focused therapies such as stereotactic radiation therapy.
These factors, together with continuous research and clinical trials, continue to promote stereotactic radiation therapy's adoption and development as a key treatment technique in oncology and other medical sectors.
China expenditure on stereotactic radiation therapy in 2022 was US$ 272.8 Million.
China approaches healthcare collaboratively, with substantial relationships between hospitals, research institutions, and industrial players.
Ongoing SRT research and clinical trials help to enhance the evidence base and improve treatment methods. The good findings of these research are driving the use of SRT in clinical practise.
In 2022, the Germany held a significant share in the global market and contributed around US$ 318.1 Million. Germany has a well-developed healthcare system that includes cutting-edge medical facilities, hospitals, and research institutes. The availability of cutting-edge radiation treatment equipment and expertise facilitates the country's extensive adoption of SRT. Germany lays a great emphasis on providing patients with least invasive treatment choices. SRT is an outpatient, non-invasive technique that delivers very precise radiation to tumors, minimising the need for open surgery. The demand for non-invasive treatments corresponds to the expansion of the SRT market in Germany.
Germany is well-known for its medical technical breakthroughs. SRT has become more precise and effective as better imaging devices, treatment planning software, and real-time tumor tracking technologies have been developed and adopted. These technical improvements aid in the expansion of the SRT market in Germany.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By technology, linear accelerator radiosurgery systems held 68.9% market share in world in 2022.
A linear accelerator radiation therapy tailors high-energy radiation such as x-rays or electrons to conform to the contour of a tumor to damage cancer cells while preserving normal tissue in the surrounding area. It has numerous built-in safety safeguards to ensure that it delivers the correct dose and is frequently examined by a medical physicist to confirm that it is functioning properly. This precise treatment use of technology is helping these therapies gain popularity.
CNS cancer held 24.5% market share in 2022 globally.
SRS reduces the risk of haemorrhage, infection, and anaesthesia associated with surgery. It is an outpatient procedure that involves little interruption of other therapies, like as chemotherapy. The outcomes of SRS for brain metastases or other CNS malignancies appear to be comparable to those of surgery to remove the tumor. This is the rationale for the widespread use of these technologies in CNS cancer treatment around the world.
The hospitals have a considerable presence in the stereotactic radiation therapy market, accounting for 42.2% value share in 2022, and exhibit a high CAGR of 6.2% over the forecast period. The increased use of SRT in hospitals is a result of more data generated during cancer diagnosis and treatment, as well as increased patient visits globally each year. Increasing government initiatives aimed at providing hospitals with cutting-edge technology are a few of the factors driving this market's expansion.
Collaboration in research & development, and commercialization to expand market and create technologically advanced systems with new-edge applications are key strategies adopted by key players. Numerous large firms compete in the field of stereotactic radiation therapy. Among the well-known players in this field are:
Similarly, recent developments related to the company’s manufacturing the stereotactic radiation therapy systems have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value, Units for Volume |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, Nordics, China, Japan, South Korea, India, Indonesia, Thailand, Philippines, Vietnam, Malaysia, Australia, New Zealand, GCC countries, Türkiye, Israel, Northern Africa and South Africa. |
| Key Market Segments Covered | Technology, Indication, End User, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market is valued at US$ 3.9 billion in 2023.
The market is likely to register a CAGR of 7.3% from 2023 to 2033.
The market is projected to value at US$ 7.9 billion in 2033.
The market share of the top 5 countries is 62.6%.
Technological advancements in radiation therapy are likely to provide a boost to the market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions & Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value Added Insights
4.1. Product Adoption / Usage Analysis
4.2. Installed Base Scenario
4.3. Disease Epidemiology by Key Indications
4.4. Technology Assessment
4.5. Regulatory Scenario
4.6. Reimbursement Landscape
4.7. PESTLE Analysis
4.8. Porter’s Analysis
4.9. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure
5.1.2. Global Life Expectancy Outlook
5.1.3. Global Radiation Therapy Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Top Companies Historical Growth
5.2.2. Technological Advancements in Stereotactic Radiation Therapy
5.2.3. New Product Launches
5.2.4. Ease of Treatment in Outpatient Basis
5.2.5. Improved Access to Healthcare Services
5.2.6. Increasing Minimally Invasive Treatment Options
5.2.7. Cost of Products
5.2.8. Increasing Prevalence of Cancer
5.2.9. Favorable Policies by Government
5.2.10. Strategic Mergers and Acquisitions among Players
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand Volume Analysis 2017 –2022 and Forecast, 2023 to 2033
6.1. Historical Market Volume (Units) Analysis, 2017 –2022
6.2. Current and Future Market Volume (Units) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
7. Global Market - Pricing Analysis
7.1. Regional Pricing Analysis, By-Product
7.2. Pricing Break Up
7.2.1. Manufacturer Level
7.2.2. Distributor Level
7.3. Global Average Pricing Analysis Benchmark
7.4. Pricing Assumptions
8. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
8.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
8.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
8.2.1. Y-o-Y Growth Trend Analysis
8.2.2. Absolute $ Opportunity Analysis
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Technology
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Technology, 2017 to 2022
9.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Technology, 2023 to 2033
9.3.1. Linear Accelerator Radiosurgery Systems
9.3.2. GammaKnife Radiosurgery Systems
9.3.3. Proton Beam Therapy
9.3.4. CyberKnife
9.4. Market Attractiveness Analysis, By Technology
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Indication
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Indication, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Indication, 2023 to 2033
10.3.1. CNS Cancer
10.3.2. Prostate Cancer
10.3.3. Head and Neck
10.3.4. Breast Cancer
10.3.5. Lung Cancer
10.3.6. Other
10.4. Market Attractiveness Analysis, By Indication
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis, By End User, 2017 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast, By End User, 2023 to 2033
11.3.1. Hospitals
11.3.2. Imaging Centers
11.3.3. Cancer Research Centers
11.3.4. Oncological Treatment Centers
11.4. Market Attractiveness Analysis, By End User
12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Region, 2017 to 2022
12.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Region, 2023 to 2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (Middle East & Africa)
12.4. Market Attractiveness Analysis, By Region
13. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis, By Market Taxonomy, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. U.S.
13.3.1.2. Canada
13.3.2. By Technology
13.3.3. By Indication
13.3.4. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Technology
13.4.3. By Indication
13.4.4. By End User
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
13.7. Market Trends
13.8. Country Level Analysis & Forecast
13.8.1. U.S. Market
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast, By Market Taxonomy
13.8.1.2.1. By Technology
13.8.1.2.2. By Indication
13.8.1.2.3. By End User
13.8.2. Canada Market
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast, By Market Taxonomy
13.8.2.2.1. By Technology
13.8.2.2.2. By Indication
13.8.2.2.3. By End User
14. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis, By Market Taxonomy, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Technology
14.3.3. By Indication
14.3.4. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Technology
14.4.3. By Indication
14.4.4. By End User
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
14.7. Market Trends
14.8. Country Level Analysis & Forecast
14.8.1. Brazil Market
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast, By Market Taxonomy
14.8.1.2.1. By Technology
14.8.1.2.2. By Indication
14.8.1.2.3. By End User
14.8.2. Argentina Market
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast, By Market Taxonomy
14.8.2.2.1. By Technology
14.8.2.2.2. By Indication
14.8.2.2.3. By End User
14.8.3. Mexico Market
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast, By Market Taxonomy
14.8.3.2.1. By Technology
14.8.3.2.2. By Indication
14.8.3.2.3. By End User
15. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis, By Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. U.K.
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Nordic Countries
15.3.1.8. Russia
15.3.1.9. Rest of Europe
15.3.2. By Technology
15.3.3. By Indication
15.3.4. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Technology
15.4.3. By Indication
15.4.4. By End User
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
15.7. Market Trends
15.8. Country Level Analysis & Forecast
15.8.1. Germany Market
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast, By Market Taxonomy
15.8.1.2.1. By Technology
15.8.1.2.2. By Indication
15.8.1.2.3. By End User
15.8.2. France Market
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast, By Market Taxonomy
15.8.2.2.1. By Technology
15.8.2.2.2. By Indication
15.8.2.2.3. By End User
15.8.3. Italy Market
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast, By Market Taxonomy
15.8.3.2.1. By Technology
15.8.3.2.2. By Indication
15.8.3.2.3. By End User
15.8.4. Spain Market
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast, By Market Taxonomy
15.8.4.2.1. By Technology
15.8.4.2.2. By Indication
15.8.4.2.3. By End User
15.8.5. U.K. Market
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast, By Market Taxonomy
15.8.5.2.1. By Technology
15.8.5.2.2. By Indication
15.8.5.2.3. By End User
15.8.6. BENELUX Market
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast, By Market Taxonomy
15.8.6.2.1. By Technology
15.8.6.2.2. By Indication
15.8.6.2.3. By End User
15.8.7. Nordic Countries Market
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast, By Market Taxonomy
15.8.7.2.1. By Technology
15.8.7.2.2. By Indication
15.8.7.2.3. By End User
15.8.8. Russia Market
15.8.8.1. Introduction
15.8.8.2. Market Analysis and Forecast, By Market Taxonomy
15.8.8.2.1. By Technology
15.8.8.2.2. By Indication
15.8.8.2.3. By End User
16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis, By Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Thailand
16.3.1.3. Indonesia
16.3.1.4. Malaysia
16.3.1.5. Vietnam
16.3.1.6. Philippines
16.3.1.7. Rest of South Asia
16.3.2. By Technology
16.3.3. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Technology
16.4.3. By Indication
16.4.4. By End User
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
16.7. Market Trends
16.8. Country Level Analysis & Forecast
16.8.1. India Market
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast, By Market Taxonomy
16.8.1.2.1. By Technology
16.8.1.2.2. By Indication
16.8.1.2.3. By End User
16.8.2. Indonesia Market
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast, By Market Taxonomy
16.8.2.2.1. By Technology
16.8.2.2.2. By Indication
16.8.2.2.3. By End User
16.8.3. Malaysia Market
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast, By Market Taxonomy
16.8.3.2.1. By Technology
16.8.3.2.2. By Indication
16.8.3.2.3. By End User
16.8.4. Thailand Market
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast, By Market Taxonomy
16.8.4.2.1. By Technology
16.8.4.2.2. By Indication
16.8.4.2.3. By End User
16.8.5. Vietnam Market
16.8.5.1. Introduction
16.8.5.2. Market Analysis and Forecast, By Market Taxonomy
16.8.5.2.1. By Technology
16.8.5.2.2. By Indication
16.8.5.2.3. By End User
16.8.6. Philippines Market
16.8.6.1. Introduction
16.8.6.2. Market Analysis and Forecast, By Market Taxonomy
16.8.6.2.1. By Technology
16.8.6.2.2. By Indication
16.8.6.2.3. By End User
17. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis, By Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Technology
17.3.3. By Indication
17.3.4. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Technology
17.4.3. By Indication
17.4.4. By End User
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
17.7. Market Trends
17.8. Country Level Analysis & Forecast
17.8.1. China Market
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast, By Market Taxonomy
17.8.1.2.1. By Technology
17.8.1.2.2. By Indication
17.8.1.2.3. By End User
17.8.2. Japan Market
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast, By Market Taxonomy
17.8.2.2.1. By Technology
17.8.2.2.2. By Indication
17.8.2.2.3. By End User
17.8.3. South Korea Market
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast, By Market Taxonomy
17.8.3.2.1. By Technology
17.8.3.2.2. By Indication
17.8.3.2.3. By End User
18. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis, By Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Technology
18.3.3. By Indication
18.3.4. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Technology
18.4.3. By Indication
18.4.4. By End User
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis
18.7. Market Trends
18.8. Country Level Analysis & Forecast
18.8.1. Australia Market
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast, By Market Taxonomy
18.8.1.2.1. By Technology
18.8.1.2.2. By Indication
18.8.1.2.3. By End User
18.8.2. New Zealand Market
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast, By Market Taxonomy
18.8.2.2.1. By Technology
18.8.2.2.2. By Indication
18.8.2.2.3. By End User
19. Middle East and Africa (Middle East & Africa) Market Analysis 2017 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis, By Market Taxonomy, 2017 to 2022
19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Israel
19.3.1.3. Türkiye
19.3.1.4. Northern Africa
19.3.1.5. South Africa
19.3.1.6. Rest of Middle East and Africa
19.3.2. By Technology
19.3.3. By Indication
19.3.4. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Technology
19.4.3. By Indication
19.4.4. By End User
19.5. Key Market Participants - Intensity Mapping
19.6. Drivers and Restraints - Impact Analysis
19.7. Market Trends
19.8. Country Level Analysis & Forecast
19.8.1. GCC Countries Market
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast, By Market Taxonomy
19.8.1.2.1. By Technology
19.8.1.2.2. By Indication
19.8.1.2.3. By End User
19.8.2. Israel Market
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast, By Market Taxonomy
19.8.2.2.1. By Technology
19.8.2.2.2. By Indication
19.8.2.2.3. By End User
19.8.3. Türkiye Market
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast, By Market Taxonomy
19.8.3.2.1. By Technology
19.8.3.2.2. By Indication
19.8.3.2.3. By End User
19.8.4. Northern Africa Market
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast, By Market Taxonomy
19.8.4.2.1. By Technology
19.8.4.2.2. By Indication
19.8.4.2.3. By End User
19.8.5. South Africa Market
19.8.5.1. Introduction
19.8.5.2. Market Analysis and Forecast, By Market Taxonomy
19.8.5.2.1. By Technology
19.8.5.2.2. By Indication
19.8.5.2.3. By End User
20. Market Structure Analysis
20.1. Market Analysis, By Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Concentration
20.4. Market Presence Analysis
20.4.1. Regional Footprint Analysis
20.4.2. Product Footprint Analysis
20.4.3. Channel Footprint Analysis
21. Competition Analysis
21.1. Competition Dashboard
21.2. Branding and Promotional Strategies, By Key Players
21.3. Key Development Analysis
21.4. Competition Deep Dive
21.4.1. Mevion Medical Systems, Inc.
21.4.1.1. Overview
21.4.1.2. Product Portfolio
21.4.1.3. Key Financials
21.4.1.4. SWOT Analysis
21.4.1.5. Sales Footprint
21.4.1.6. Strategy Overview
21.4.1.7. Key Developments
21.4.1.7.1. Marketing Strategies
21.4.1.7.2. Product Strategies
21.4.1.7.3. Channel Strategies
21.4.2. Accuray Incorporated
21.4.2.1. Overview
21.4.2.2. Product Portfolio
21.4.2.3. Key Financials
21.4.2.4. SWOT Analysis
21.4.2.5. Sales Footprint
21.4.2.6. Strategy Overview
21.4.2.7. Key Developments
21.4.2.7.1. Marketing Strategies
21.4.2.7.2. Product Strategies
21.4.2.7.3. Channel Strategies
21.4.3. MASEP Medical Science & Technology Development (Shenzhen) Co
21.4.3.1. Overview
21.4.3.2. Product Portfolio
21.4.3.3. Key Financials
21.4.3.4. SWOT Analysis
21.4.3.5. Sales Footprint
21.4.3.6. Strategy Overview
21.4.3.7. Key Developments
21.4.3.7.1. Marketing Strategies
21.4.3.7.2. Product Strategies
21.4.3.7.3. Channel Strategies
21.4.4. Akesis, Inc
21.4.4.1. Overview
21.4.4.2. Product Portfolio
21.4.4.3. Key Financials
21.4.4.4. SWOT Analysis
21.4.4.5. Sales Footprint
21.4.4.6. Strategy Overview
21.4.4.7. Key Developments
21.4.4.7.1. Marketing Strategies
21.4.4.7.2. Product Strategies
21.4.4.7.3. Channel Strategies
21.4.5. Elekta
21.4.5.1. Overview
21.4.5.2. Product Portfolio
21.4.5.3. Key Financials
21.4.5.4. SWOT Analysis
21.4.5.5. Sales Footprint
21.4.5.6. Strategy Overview
21.4.5.7. Key Developments
21.4.5.7.1. Marketing Strategies
21.4.5.7.2. Product Strategies
21.4.5.7.3. Channel Strategies
21.4.6. Hitachi, Ltd. (Mitsubishi Electric Corporation)
21.4.6.1. Overview
21.4.6.2. Product Portfolio
21.4.6.3. Key Financials
21.4.6.4. SWOT Analysis
21.4.6.5. Sales Footprint
21.4.6.6. Strategy Overview
21.4.6.7. Key Developments
21.4.6.7.1. Marketing Strategies
21.4.6.7.2. Product Strategies
21.4.6.7.3. Channel Strategies
21.4.7. Siemens Healthineers AG (Varian Medical Systems, Inc.)
21.4.7.1. Overview
21.4.7.2. Product Portfolio
21.4.7.3. Key Financials
21.4.7.4. SWOT Analysis
21.4.7.5. Sales Footprint
21.4.7.6. Strategy Overview
21.4.7.7. Key Developments
21.4.7.7.1. Marketing Strategies
21.4.7.7.2. Product Strategies
21.4.7.7.3. Channel Strategies
21.4.8. Ion Beam Applications
21.4.8.1. Overview
21.4.8.2. Product Portfolio
21.4.8.3. Key Financials
21.4.8.4. SWOT Analysis
21.4.8.5. Sales Footprint
21.4.8.6. Strategy Overview
21.4.8.7. Key Developments
21.4.8.7.1. Marketing Strategies
21.4.8.7.2. Product Strategies
21.4.8.7.3. Channel Strategies
21.4.9. ProTom International
21.4.9.1. Overview
21.4.9.2. Product Portfolio
21.4.9.3. Key Financials
21.4.9.4. SWOT Analysis
21.4.9.5. Sales Footprint
21.4.9.6. Strategy Overview
21.4.9.7. Key Developments
21.4.9.7.1. Marketing Strategies
21.4.9.7.2. Product Strategies
21.4.9.7.3. Channel Strategies
21.4.10. Pronova Solutions
21.4.10.1. Overview
21.4.10.2. Product Portfolio
21.4.10.3. Key Financials
21.4.10.4. SWOT Analysis
21.4.10.5. Sales Footprint
21.4.10.6. Strategy Overview
21.4.10.7. Key Developments
21.4.10.7.1. Marketing Strategies
21.4.10.7.2. Product Strategies
21.4.10.7.3. Channel Strategies
21.4.11. Sumitomo Heavy Industries, Ltd.
21.4.11.1. Overview
21.4.11.2. Product Portfolio
21.4.11.3. Key Financials
21.4.11.4. SWOT Analysis
21.4.11.5. Sales Footprint
21.4.11.6. Strategy Overview
21.4.11.7. Key Developments
21.4.11.7.1. Marketing Strategies
21.4.11.7.2. Product Strategies
21.4.11.7.3. Channel Strategies
21.4.12. Provision Cares
21.4.12.1. Overview
21.4.12.2. Product Portfolio
21.4.12.3. Key Financials
21.4.12.4. SWOT Analysis
21.4.12.5. Sales Footprint
21.4.12.6. Strategy Overview
21.4.12.7. Key Developments
21.4.12.7.1. Marketing Strategies
21.4.12.7.2. Product Strategies
21.4.12.7.3. Channel Strategies
21.4.13. Optivus Proton Therapy Inc.
21.4.13.1. Overview
21.4.13.2. Product Portfolio
21.4.13.3. Key Financials
21.4.13.4. SWOT Analysis
21.4.13.5. Sales Footprint
21.4.13.6. Strategy Overview
21.4.13.7. Key Developments
21.4.13.7.1. Marketing Strategies
21.4.13.7.2. Product Strategies
21.4.13.7.3. Channel Strategies
21.4.14. Advanced Oncotherapy
21.4.14.1. Overview
21.4.14.2. Product Portfolio
21.4.14.3. Key Financials
21.4.14.4. SWOT Analysis
21.4.14.5. Sales Footprint
21.4.14.6. Strategy Overview
21.4.14.7. Key Developments
21.4.14.7.1. Marketing Strategies
21.4.14.7.2. Product Strategies
21.4.14.7.3. Channel Strategies
21.4.15. Sun Nuclear Corporation
21.4.15.1. Overview
21.4.15.2. Product Portfolio
21.4.15.3. Key Financials
21.4.15.4. SWOT Analysis
21.4.15.5. Sales Footprint
21.4.15.6. Strategy Overview
21.4.15.7. Key Developments
21.4.15.7.1. Marketing Strategies
21.4.15.7.2. Product Strategies
21.4.15.7.3. Channel Strategies
21.4.16. B dot Medical Inc. (partnered with Toshiba)
21.4.16.1. Overview
21.4.16.2. Product Portfolio
21.4.16.3. Key Financials
21.4.16.4. SWOT Analysis
21.4.16.5. Sales Footprint
21.4.16.6. Strategy Overview
21.4.16.7. Key Developments
21.4.16.7.1. Marketing Strategies
21.4.16.7.2. Product Strategies
21.4.16.7.3. Channel Strategies
22. Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Stereotactic Radiation Therapy Market
